Outsourcing-Pharma: FHI Clinical tackles COVID-19 immunotherapy in clinical trial

April 16, 2020

Our president and CEO, Ted FitzGerald, recently spoke with Jenni Springer, editor of Outsourcing-Pharma, about the COVID-19 immunotherapy trial on which FHI Clinical is partnering with the Infectious Disease Research Institute (IDRI). FHI Clinical is providing full-service CRO capabilities, including project management, medical and clinical monitoring, and data and safety analysis for the trial.

“In this period of crisis, we are incredibly grateful to be able to contribute to understanding of the treatment of COVID-19 through this partnership.”
– Ted FitzGerald, President and CEO, FHI Clinical

In his interview, Ted spoke of the connection FHI Clinical and IDRI made through the Global Health Clinical Consortium (GHCC), an initiative funded by the Bill and Melinda Gates Foundation. Both FHI Clinical and IDRI are long-standing members of GHCC and have teamed together in the past on other studies related to neglected diseases.

FHI Clinical leverages its unique history of working in challenging environments, often in low-income countries, research-naïve sites and outbreak settings. The company has stood up and managed large trials during the 2014-2015 Ebola outbreak in Sierra Leone and the more recent Zika outbreak in Latin America and the Caribbean, among others. One of FHI Clinical’s differentiators is that the company has the experience and expertise to move quickly and nimbly to support trials like this IDRI-led study.

According to Ted, the study is “currently in rapid start-up with the goal of subject enrollment before the U.S. pandemic is expected to decline.”

For more of Ted’s interview, check out the Outsourcing-Pharma article.

Learn more about FHI Clinical’s collaboration with IDRI for this Celularity-funded study.

news archive

Five members added to the FHI Clinical Scientific Advisory Expert team

June 25, 2020
Several months ago, FHI Clinical began recruiting scientific and technological experts to join our newly formed panel of Scientific Advisory Experts, which was created to promote best practices, build alliances and spur innovation in the clinical trials research field. Today, we are pleased to announce that we have appointed five new members.

Read More »

Triangle Business Journal: Going Virtual

June 12, 2020
Claudia Christian, Senior VP, Clinical Operations, recently spoke with Seth Gulledge, writer for the Research Triangle Park, North Carolina-based Triangle Business Journal, about how the COVID-19 pandemic has disrupted the traditional model for clinical trials. This has prompted CROs around the Triangle to rapidly integrate virtual trial models to speed up clinical research and push COVID-19 vaccines and therapies to market.

Read More »


June 8, 2020
Today, we commit to being better and doing more. We will continue consulting and partnering with the communities where we work, and we will redouble our efforts to ensure that their voices inform and shape the way we do our work. We will reexamine our internal structures and evolve our practices to root out imbalances and inequality and ensure that everyone is represented, included and empowered.

Read More »

Share this post

Share on linkedin
Share on twitter
Share on facebook